AXT's Indium Phosphide Ramp Delivers A Beat And A ~$90 Million Guide, But The Stock Still Trades Like A Skeptic's Story

AXT turned in the kind of quarter that changes the conversation around a small-cap substrate maker. GAAP earnings of $0.39 per share beat the $0.30 consensus by 18.2% and cleared the $0.33 Earnings Whisper number. Revenue reached a record $73.41 million, 11.0% above the $66.11 million consensus. A year ago AXT lost $0.04 per share, so earnings grew 1075.0% while revenue rose 162.6%. The central takeaway is not the beat itself. It is that management raised nearly every forward marker at once: margins, backlog, capacity and guidance. Q4 is guided to roughly $90 million in revenue and $0.57 to $0.59 in non-GAAP EPS, above estimates.

The beat held up well on inspection. Indium phosphide revenue climbed to $54.3 million from $30.7 million in Q2 and just $8.0 million in Q4 of last year, and it now accounts for most of the business. Non-GAAP gross margin expanded to 56.1% from 45.0% in Q2, 29.9% in Q1 and 21.5% four quarters ago. Operating income was $28.4 million against a loss a year earlier. There are qualifiers. Net interest income of $5.9 million, earned on a balance sheet swollen by equity raising, contributed a meaningful slice of the $34.3 million in pretax income. Another $4.0 million of profit went to noncontrolling interests. Diluted shares also rose to 65.9 million from 43.8 million, so per-share gains came despite heavy dilution. Even so, the operating line alone shows a business whose economics have fundamentally reset.

The call made the growth story more credible. Backlog topped $500 million, up from above $100 million in Q1 and Q2. Management said the increase is driven mostly by run-rate business rather than long-term agreements. Every customer is on allocation, lead times exceed nine months, and InP prices are rising. AXT surpassed its goal of doubling 2026 capacity in August. It now expects to exit the year at 2.75 to 3 times end-2025 levels and is targeting another doubling in 2027. The InP revenue opportunity went from "more than triple" on the Q2 call to "more than quadrupled." Mix should also help: 6-inch InP has reached pilot production, laser substrates are migrating to 4-inch in 2027, and the CFO now expects gross margin with a "6" handle next quarter. Notably, the Q4 guide carries none of the export-permit caveat that hedged the prior outlook.

The guide does contain one subtle point worth noting. Q3 added about $25.8 million sequentially, while the ~$90 million Q4 target implies a smaller add of roughly $16.6 million. That gap reflects capacity limits rather than demand, but it does mean sequential growth is moderating. Bears also have legitimate ammunition elsewhere:

• Indium raw material costs are rising significantly.
• Non-GAAP operating expenses are stepping up to about $13 million.
• Initial 6-inch yields are expected to be low.
• GaAs should be seasonally soft in Q4.
• The up-to-$545 million Tongmei private equity financing funds expansion but would cut AXT's stake to about 73.4%, and the Hong Kong IPO is still about a year away.
• Management is deliberately leaning away from formal LTAs. That preserves pricing flexibility but reduces contractual visibility, at a time when investors are already worried about InP overcapacity and new Chinese entrants.
• Reliance on China export permits and China concentration remain structural risks.

The market setup is more complicated than the surprise implies. Shares closed at $64.38 before the report, 3.5% below the open following the July release. That small net change masks a violent round trip: the stock ran to $97.79 in mid-August, collapsed to $50.57 on October 16, and has since recovered 27.3%. It entered earnings sitting almost exactly on its 200-day moving average of $64.29, still 34.2% below the quarter's high. Investor sentiment stayed mildly negative and was essentially unchanged, edging from -0.127 to -0.115. The Earnings Whispers trend readings were mixed, with momentum positive while price and AVWAP trends remained negative. Taken together, investors did not appear positioned for results this strong, but they also had not abandoned the overcapacity concern.

The bottom line is that AXT delivered an accelerating inflection in InP revenue, gross margin and backlog, then guided higher without the permit hedge that tempered last quarter's outlook. The open questions are no longer about demand. They center on execution of the capacity ramp, indium cost pressure, Tongmei dilution, and whether new supply erodes today's tight pricing. With the stock sitting at its 200-day average and sentiment still cautious, the report raises the fundamental bar the skeptics now have to argue against.

Read our earnings preview for AXT, Inc.: https://www.earningswhispers.com/article/AXTI/21168

This earnings review was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.